Biolexis Therapeutics

Biolexis Therapeutics

https://www.biolexistx.com/

Biolexis Therapeutics is a biotechnology company that has developed BLX-7006, a first-in-class oral small-molecule GLP-1 receptor agonist, using their AI-driven platform MolecuLern.

Biolexis Therapeutics Advances GLP-1 Receptor Activation with AI

March 15, 2025

Biolexis Therapeutics has confirmed a novel allosteric activation mechanism for the GLP-1 receptor using its AI-driven platform, MolecuLern, as announced in a press release.
Free newsletter

Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates